Impel NeuroPharma touts proof-of-concept trial for intranasal migraine drug

This article was originally published here
Share

Privately-held biotech Impel NeuroPharma touted positive results today from a Phase I trial of its acute migraine headache therapy.

The Seattle-based company’s drug is delivered intranasally using its Precision Olfactory Delivery device, which is designed to deliver drugs to the upper nasal cavity and target the brain using the olfactory and trigeminal nerves.

Get the full story at our sister site, Drug Delivery Business News.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply